Search

everythinglearnresearchcommunity

for

Search:↓

The user is experiencing hair improvement in the central and back areas after using finasteride, minoxidil, and a galenic lotion, but the temple area is worsening. They suspect the lotion might be causing the issue and are considering stopping its use.

A user is starting a topical finasteride treatment for diffuse patterned alopecia, having previously used minoxidil without success. They are cautious about side effects and have chosen topical over oral finasteride, while also using Nizoral and biotin in their routine.

User is experiencing issues with Minoxidil and is considering switching to Redensyl, specifically asking for brand recommendations. The Ordinary - Multi Peptide is mentioned, but the user seeks other brand experiences.

The user experiences significant hair shedding during seasonal changes while using oral minoxidil 2.5mg and finasteride 1mg daily. They question if shedding miniaturized hairs is normal or if a stronger treatment is needed.

A clean diet, including cutting sugar, gluten, and dairy, improved hair health and reduced shedding for a user on oral minoxidil and finasteride, but reverting to an old diet worsened hair condition. While diet impacts hair health, genetic factors and treatments like topical ketoconazole and hydrocortisone are also important for managing hair loss.

The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.

The user reintroduced RU58841 and noticed increased shedding and visible thinning. They have also been using dutasteride and oral minoxidil for 2 years.

Treating the itch associated with male pattern baldness, which is believed to be caused by DHT. Potential treatments discussed include salt water, finasteride, ketoconazole, and RU58841.

The user experienced severe side effects from finasteride, including anxiety and libido issues, and is currently using topical minoxidil and microneedling. They are considering trying dutasteride but are concerned about potential side effects.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

A young person is experiencing aggressive hair loss and not responding well to minoxidil and finasteride. Suggestions include trying dutasteride, hair systems, lifestyle changes, or considering a wig.

The user's experience with hair loss, their doctor explaining that they were likely hyper aware of thin spots due to anxiety and an underlying whorl in one area, and providing encouragement for those feeling discouraged. Treatments mentioned include minoxidil and spironolactone.

A user is frustrated about early balding despite older male relatives retaining hair into old age. Another user plans to start finasteride soon to address their hair thinning.

The user is experiencing hair thinning and brittleness, possibly due to Telogen Effluvium, which affects body hair and may be linked to stress or nutrition. They are considering using finasteride for treatment but are unsure if it will address their symptoms.

PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

The user experienced hair shedding after increasing minoxidil from 5% to 7% with latanoprost, possibly causing telogen effluvium. They are on HRT with Lupron, Estradiol, and Raloxifene, and are concerned about the shedding's duration.

The user has been using minoxidil and finasteride for hair loss without positive results and switched to dutasteride 1.5 months ago. They suspect seborrheic dermatitis might be affecting the effectiveness of these treatments.

The conversation is about a user experiencing hair shedding after switching from finasteride to dutasteride and increasing their oral minoxidil dose. The user is advised to continue with the current treatment, consider adding topical minoxidil, and consult a dermatologist for potential underlying issues.

PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.

The user experienced a panic attack after adding 5% topical minoxidil to their routine, which already included oral finasteride and minoxidil, and microneedling. They are seeking advice on whether microneedling increased absorption and if the anxiety attacks will subside.

A 25-year-old male is experiencing worsening hair loss after 3 months of using topical minoxidil, finasteride, and Redensyl, with users suggesting patience, potential hormonal factors, and considering alternative treatments like dutasteride and oral minoxidil. Shedding is noted as a common phase, indicating potential future hair regrowth.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The user experienced anxiety and heart pounding from oral minoxidil, despite its effectiveness, and switched back to topical minoxidil. After managing anxiety, they found oral minoxidil more effective, but side effects differ for each person.

A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.

The user is experiencing an itchy scalp and acne while using oral dutasteride and minoxidil for hair loss. They are considering stopping minoxidil to see if symptoms improve and possibly switching to finasteride if needed.

The conversation discusses concerns about body dysmorphia related to hair loss, with some users expressing frustration over posts claiming treatments like finasteride and dutasteride are ineffective or harmful despite minimal hair loss. It emphasizes the importance of early treatment with medications like finasteride and minoxidil for those experiencing hair loss.

Rhamnose may promote hair growth and pigmentation, suggesting it as a potential hair loss treatment. The conversation discusses its potential alongside known treatments like Minoxidil, finasteride, and RU58841.

The user experienced aggressive hair loss despite using oral finasteride and minoxidil, with additional issues like dandruff and eyebrow hair loss. They are considering switching to oral minoxidil and dutasteride due to scalp inflammation and lack of improvement.

Taurine shows potential in combating hair loss caused by chemical stress, especially when combined with other treatments like finasteride. Finasteride demonstrated better stress-reducing effects in the study.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.